Impressions from Boston by Björn Walse, CEO, SARomics Biostructures

I had the great pleasure to visit Boston the last two weeks of September. The reason for the trip was to participate in BioPharm America 2013 (#BPA13) and Discovery on Target 2013 (#DOTBoston13). This blog is about my impressions from the last of these meetings and from my stay in the area. 

After three intensive days packed with excellent talks about epigenetics readers, writers and erasers I am completely astonished at how fast this field is moving forward. For example, the lysine…

Read More

Impressions from the meeting “Fragments 2013”

Early last week the 4th RSC-BMCS Fragment-based Drug Discovery meeting was held at STFC Rutherford Appleton Laboratory, Oxfordshire, UK. The meeting started with an introductory course for those new to the field. This was followed by several seminars that covered library design, screening methodologies, examples of fragment based applications and success stories.
Fragment-based drug discovery is based on the fact that it is (in a relative sense!) easier to use small molecules as starting points…

Read More

SARomics Biostructures is represented in Almedalen, Swedish policy makers meeting

As CSO for SARomics Biostructures I yesterday had the great pleasure of taking part in a panel debate that was part of Almedal Week, in Visby, Gotland. Almedal Week started way back in 1968 when Olof Palme, Swedish prime minister at that time, spoke from the back of a lorry, but is now a gathering point for literally thousands of representatives for every sector of Swedish society. The purpose of the debate was to highlight the world-leading scientific possibilities offered by the two new major…

Read More